KRAS and RAS inhibitor trial starts by region

3 regions, 2020 to 2025

56 Global, 2025

KRAS and RAS inhibitor trial starts by region: 3 regions, 2020 to 2025KRAS and RAS inhibitor trial starts by region: 3 regions, 2020 to 2025. 3 regions on one axis: Global, China, United States. 18 observations from 2020 to 2025, ranging from 1 to 226. Latest values: Global 56 (2025); China 24 (2025); United States 24 (2025). 0 50 100 150 200 250 2020 2021 2022 2023 2024 2025 Global China United States
KRAS and RAS inhibitor trial starts by region: 3 regions, 2020 to 2025KRAS and RAS inhibitor trial starts by region: 3 regions, 2020 to 2025. 3 regions on one axis: Global, China, United States. 18 observations from 2020 to 2025, ranging from 1 to 226. Latest values: Global 56 (2025); China 24 (2025); United States 24 (2025). 0 100 200 300 2020 2021 2022 2023 2024 2025 Global China United States
KRAS and RAS inhibitor trial starts by region: 3 regions, 2020 to 2025KRAS and RAS inhibitor trial starts by region: 3 regions, 2020 to 2025. 3 regions on one axis: Global, China, United States. 18 observations from 2020 to 2025, ranging from 1 to 226. Latest values: Global 56 (2025); China 24 (2025); United States 24 (2025). 0 100 200 300 2020 2021 2022 2023 2024 2025 Global China United States
View the underlying data
KRAS and RAS inhibitor trial starts by region: 3 regions, 2020 to 2025
Region Period Type Value
Global 2025 Actual 56
Global 2024 Actual 60
Global 1 Jan 2023 to 27 Sep 2026 Actual 226
Global 2022 Actual 37
Global 2021 Actual 23
Global 2020 Actual 13
China 2025 Actual 24
China 2024 Actual 25
China 2023 Actual 16
China 2022 Actual 11
China 2021 Actual 8
China 2020 Actual 1
United States 2025 Actual 24
United States 2024 Actual 34
United States 1 Jan 2023 to 27 Sep 2026 Actual 116
United States 2022 Actual 22
United States 2021 Actual 20
United States 2020 Actual 11
Chart: StatOrigin · Source: ClinicalTrials.gov · statorigin.org CC BY 4.0